Modality
Degrader
MOA
CDK2i
Target
AuroraA
Pathway
Wnt
Wet AMD
Development Pipeline
Preclinical
May 2025
→ Apr 2027
PreclinicalCurrent
NCT03727938
2,012 pts·Wet AMD
2025-05→2027-04·Completed
2,012 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-04-191.1y awayInterim· Wet AMD
Trial Timeline
Q3Q42026Q2Q3Q42027Q2
Preclinical
Complet…
Catalysts
Interim
2027-04-19 · 1.1y away
Wet AMD
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03727938 | Preclinical | Wet AMD | Completed | 2012 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D |